Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 4/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16831914 | 0.86 | CPB2 (0.45) | SMN1; SMN2CPB2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL6369922 | 0.85 | CPB2 (0.39) | CYP4F2CYP4A11LMNARAB9ASMN1; SMN2 | |
| SCHEMBL11571898 | 0.84 | CPB2 (0.47) | LMNACPB2TNF | |
| SCHEMBL6133025 | 0.83 | CYP2C9 (0.49) | CYP4F2CYP4A11LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL9093669 | 0.83 | MEN1 (0.45) | CYP4F2CYP4A11LMNAALDH1A1 | |
| SCHEMBL7278477 | 0.81 | CPB2 (0.48) | CPB2L3MBTL1TBXAS1 | |
| SCHEMBL6376084 | 0.79 | CYP4F2 (0.41) | CYP4F2CYP4A11LMNACPB2L3MBTL1 | |
| SCHEMBL16852878 | 0.76 | MAPT (0.42) | LMNARAB9ASMN1; SMN2CPB2ALDH1A1 | |
| SCHEMBL1025097 | 0.75 | RAB9A (0.52) | RAB9ASMN1; SMN2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL14790038 | 0.75 | CPB2 (0.50) | CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153964-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153964-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | LYPLAL1, PLA2G12A, ENPP2 | CYP4F2 820/4885CYP4A11 976/4885LMNA 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.